Alexza publishes pivotal study of inhalable anti-agitation loxapine
This article was originally published in Scrip
Executive Summary
Alexza Pharmaceuticals has reported publication of one of its pivotal Phase III trials, showing that, in schizophrenia patients, its inhalable form of the generic antipsychotic drug loxapine, AZ-004, significantly reduced agitation compared with placebo as assessed by primary and secondary endpoints. The product is delivered with the company's investigational hand-held inhaler, which is trade-named Staccato.